PNC Financial Services Group
ACTU

PNC Financial Services Group’s Actuate Therapeutics ACTU Stock Holding History

PNC Financial Services Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47 Buy
+17
New +$70 ﹤0.01% 5128
2025
Q4 		– Sell
-384
Closed -$2.57K – 5333
2025
Q3 		$2.57K Buy
+384
New +$2.78K ﹤0.01% 4434

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PNC Financial Services Group's ACTU Position: Q1 2026 in Review

PNC Financial Services Group opened a new position in Actuate Therapeutics (ACTU) in Q1 2026: 17 shares worth $47. The stake represents ﹤0.01% of the portfolio and ranks #5128 among its holdings. This is a return to the name: PNC Financial Services Group previously reported a position in ACTU as recently as Q3 2025.

PNC Financial Services Group first reported a position in ACTU in Q3 2025 and has held it in 2 quarters since. The position peaked at $2.57K in Q3 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • PNC Financial Services Group held 17 shares of Actuate Therapeutics worth $47 as of Q1 2026.
  • Actuate Therapeutics was a new PNC Financial Services Group position in Q1 2026.
  • Actuate Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #5128 holding.
  • PNC Financial Services Group first reported a position in Actuate Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • PNC Financial Services Group's Actuate Therapeutics position peaked at $2.57K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.